Get started
Author

Hanneke van der Wijngaart

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs
2019 · D. L. van der Velden, L. R. Hoes, et al. · Nature · 259
Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
2022 · Louisa R. Hoes, Jade M. van Berge Henegouwen, et al. · Clinical Cancer Research · 85
PDF
Personalised reimbursement: a risk-sharing model for biomarker-driven treatment of rare subgroups of cancer patients
2019 · S.B. van Waalwijk van Doorn-Khosrovani, A. Pisters-van Roy, et al. · Annals of Oncology · 39
PDF
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types
2021 · Hanneke van der Wijngaart, Louisa R. Hoes, et al. · Clinical Cancer Research · 36
PDF
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D‐CDK4 /6 pathway alterations in the Dutch DRUP and Australian MoST trials
2023 · Laurien J. Zeverijn, Eleonora J. Looze, et al. · International Journal of Cancer · 28
Trastuzumab and pertuzumab combination therapy for advanced pre-treated HER2 exon 20-mutated non-small cell lung cancer
2022 · J.M. van Berge Henegouwen, M. Jebbink, et al. · European Journal of Cancer · 27
Optimal treatment of opioid induced constipation in daily clinical practice – an observational study
2019 · Elisabeth C. W. Neefjes, Hanneke van der Wijngaart, et al. · BMC Palliative Care · 20
PDF
Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours
2023 · Birgit S. Geurts, Thomas W. Battaglia, et al. · BMC Cancer · 13
PDF
A 73-year-old male with jaundice and acute kidney injury. Bile cast nephropathy.
2014 · H van der Wijngaart, B van Dam, et al. · PubMed · 12
Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy
2024 · Birgit S Geurts, Laurien J Zeverijn, et al. · The Journal of Pathology · 10
PDF
Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature
2022 · J. M. van Berge Henegouwen, H. van der Wijngaart, et al. · Cancer Chemotherapy and Pharmacology · 8
PDF
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol
2024 · Laurien J. Zeverijn, Birgit S. Geurts, et al. · Clinical Cancer Research · 7
Advancing wide implementation of precision oncology: A liquid nitrogen‐free snap freezer preserves molecular profiles of biological samples
2023 · Hanneke van der Wijngaart, Sahil Jagga, et al. · Cancer Medicine · 6
PDF
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
2025 · K. Verkerk, L.J. Zeverijn, et al. · ESMO Open · 5
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
2024 · Birgit S. Geurts, Laurien J. Zeverijn, et al. · Clinical Cancer Research · 4
Efficacy and predictors of response of nivolumab in treatment-refractory MSI solid tumors: Results of a tumor-agnostic DRUP cohort.
2023 · Birgit Geurts, Laurien Joanna Zeverijn, et al. · Journal of Clinical Oncology · 4
Maximizing Treatment Opportunities: Assessing Protocol Waivers’ Impact on Safety and Outcome in the Drug Rediscovery Protocol
2024 · Jade M. van Berge Henegouwen, Laurien J. Zeverijn, et al. · Clinical Cancer Research · 2
Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics
2023 · Hanneke van der Wijngaart, Robin Beekhof, et al. · Clinical Proteomics · 2
PDF
1261P Trastuzumab/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort
2021 · J. van Berge Henegouwen, M. Jebbink, et al. · Annals of Oncology · 2
PDF
594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients
2020 · L.R. Hoes, H. van der Wijngaart, et al. · Annals of Oncology · 2
PDF
Drug Rediscovery Protocol: Expanded use of existing anticancer drugs
2019 · E.E. Voest, D.L. van der Velden, et al. · Annals of Oncology · 2
PDF
232eP Whole genome sequencing in cancer of unknown primary: A real-world analysis of impact on diagnosis and treatment
2025 · L. Scheffers, M.J. Leenders, et al. · Annals of Oncology · 1
1710P Protocol waivers and consequences on treatment safety and efficacy in the Drug Rediscovery Protocol (DRUP)
2023 · L.J. Zeverijn, J.M. van Berge Henegouwen, et al. · Annals of Oncology · 1
PDF
Supplementary Figure from Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment
2023 · Louisa R. Hoes, Jade M. van Berge Henegouwen, et al. · 1
124P Durvalumab in advanced, pre-treated microsatellite instability-high solid tumors: Results of a tumor-agnostic DRUP trial cohort
2022 · B.S. Geurts, T. Battaglia, et al. · Annals of Oncology · 1
Works count: 106
Citation count: 580
H-index: 10
I10-index: 10
Year
Topic
Type